logo
In a world of conflict, the spoils are rich from gold and guns

In a world of conflict, the spoils are rich from gold and guns

The Agea day ago

The Stockholm International Peace Research Institute (SIPRI) estimated that global military expenditure hit a record $US2.7 trillion ($4.1 trillion) in 2024, an increase of 9.4 per cent in real terms from the previous year, and the steepest annual jump since the Cold War ended.
'If 5 per cent [of GDP] becomes baseline, defence stocks stop being cyclical – they become structural. And that changes everything.'
Stephen Innes, SPI Asset Management
SIPRI highlighted the 'guns or butter' cost to social programs from the rising spending on weaponry.
'As governments increasingly prioritise military security, often at the expense of other budget areas, the economic and social trade-offs could have significant effects on societies for years to come,' warned SIPRI researcher Xiao Liang.
The big beneficiaries from this war trade are traditionally US defence giants, such as Northrop Grumman – maker of the B-2 stealth bombers and intercontinental ballistic missiles – which is now trading near multi-year highs. Virginia-based RTX, which makes the Javelin and Stinger missiles that were used heavily in the Ukraine war, has also hit record highs.
But the changing nature of warfare, where computer-guided drones and new technology such as AI are coming to the fire, has thrown up some new winners.
Shares of US tech group Palantir have soared more than 400 per cent in a year as the company cements its place in the US industrial military complex.
And investors are also noticing the impact in Europe, where Germany's new government signalled a seismic shift in March, with plans to lift strict spending controls to create a €500 billion ($896 billion) fund for defence and security.
It has had a massive impact on European stocks. Italy-based aerospace, defence and security firm Leonardo, German sensor technology company Hensoldt, and British aerospace and defence company Babcock International have seen their share prices more than double over the last year.
Korea's Hanwha Aerospace is another EU beneficiary, and its share price has soared 200 per cent over the same period.
Even Australia benefits, as shown by Hanwha recently acquiring a 9.9 per cent stake in local shipbuilder Austal, with plans to double its investment. Austal shares have tripled since last September, thanks to its contracts with the US Navy.
ASX-listed DroneShield – a maker of anti-drone technology – has tripled since February. And right on cue, it announced a $61 million European military order on Wednesday for handheld detection and counter-drone systems. This one deal exceeds its entire revenue for 2024.
Three ASX-listed defence ETFs (exchange-traded funds, which invest in defence stocks globally) from VanEck, Betashares and Global X are all up 50 per cent this year.
'Global defence has been one of the few equity segments that have outperformed the market this year. Flows into ASX-listed global defence ETFs have shot up since March,' VanEck's Jamie Hannah said.
The surge in the performance of defence stocks has posed a conundrum for some ethical funds and investment mandates, which have generally precluded any military assets.
But investors appear to be coming to the conclusion that Citi reached in 2022: 'Defence is likely to be increasingly seen as a necessity that facilitates ESG as an enterprise as well as maintaining peace, stability and other social goods.'
In April, UBS Asset Management – which oversees $US1.8 trillion in investments – scrapped prohibitions that prevented its sustainable funds from investing in conventional military weapons manufacturers. Exclusions still apply to more controversial weaponry such as cluster munitions.
Hannah says VanEck already screens out these more controversial manufacturers from its ETF.
'It's very much an area where you need to consider what you're investing in,' Hannah said.
Meanwhile, the only controversy over the ultimate defensive asset, gold, is whether it has peaked after a spectacular run over the past year to a record high of $US3500 an ounce in April.
This month, a European Central Bank report confirmed that its soaring price, along with bullion buying by central banks, means gold is currently the second-biggest reserve holding by central banks behind the US dollar.
Citi highlighted the extraordinary rush to gold with a report saying 0.5 per cent of global GDP was being spent on gold – the most in 50 years of data.
And central banks have not been the only buyers. This month, VanEck noted that Australia's most recent export figures included $11 billion in 'non-monetary' gold exports to the US – which is gold acquired by private buyers, not reserve banks, for their foreign exchange reserves.
'This volume of gold exports for the quarter is more than the total non-monetary gold we have shipped to the USA in the last four years, and we think this could reflect a massive increase in demand from investors due to a loss of faith in [the US dollar] and US Treasuries,' VanEck's Cameron McCormack said.
While some are getting squeamish after this year's 27 per cent gain for the precious metal, others are expecting its golden run to continue.
Wall Street giant Goldman Sachs predicts gold will climb to $US3700 a troy ounce by the end of the year, from about $US3330 currently, as central banks keep buying tonnes of it every month.
It could rise even further if investors use bullion as a safe space ahead of interest rate cuts and amid rising recession concerns. 'In the event of a recession, Goldman Sachs Research forecasts that gold could rise to as much as $US3880 a troy ounce,' the investment bank says.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Estrella lands $5M to fuel Timor-Leste manganese exploration push
Estrella lands $5M to fuel Timor-Leste manganese exploration push

West Australian

time30 minutes ago

  • West Australian

Estrella lands $5M to fuel Timor-Leste manganese exploration push

ASX-listed Estrella Resources has pulled in a hefty $5 million from a strategic Western Australian investor, who is keen to back the company's ambitious manganese and limestone exploration campaigns in Timor-Leste. The cash came after MJ Ratta Investments exercised the second tranche of an option subscription agreement, inked in September last year. Subject to shareholder approval, the investor will receive 136.76 million shares at 3.656 cents per share, which is a 20 per cent discount to Estrella's 10-day volume-weighted average price of 4.57c. The first tranche raised $350,000 from the issue of 53.3 million shares at 0.006c per share. Estrella says the move is a major endorsement of the company's fast-moving strategy in a region that, until now, has never seen modern drilling for metallic minerals. The new funding package boosts Estrella's balance sheet and also comes with attractive terms for Ratta. The investor will gain an increased gross revenue royalty from manganese production – up from 0.25 per cent to 0.5 per cent - and an extended royalty life from five to seven years if production gets up. Additionally, the company has pledged a first-ranking security interest on its Spargoville nickel mineral rights until it can confirm delivery of 20,000 tonnes of ore to port. With the blessing of local Timor-Leste communities and its nascent mining industry, Daws added that Estrella has also received staunch support from its institutional shareholders. The funds will be used to ramp up Estrella's ongoing 3000-metre diamond and 10,000m reverse circulation drilling blitz and pave the way for a follow-up 10,000m reverse circulation campaign, subject to results. The timing of the new cash has come at an exciting time for the company, which recently landed some big manganese results. Last week, the drill bit struck a standout 7.76m hit of manganese oxide from just 30 centimetres below surface at its Ira Miri project in the country's northwest. The discovery came from a diamond drill hole using an upgraded rig, which twinned the project's first hole that had earlier pulled up short in mineralisation. Fitted with an appropriate drill bit and improved drilling fluids, the rig is capable of churning through the harder material, leading to an improved core recovery. Core visuals revealed thick, high-grade manganese zones, with some sections potentially hitting 100 per cent manganese oxide. Notably, the intercepts are already rivalling Australia's renowned Groote Eylandt deposit, which averages just 3m wide. Estrella says the material appears to be in-situ supergene enrichment from the Noni Formation and looks extremely well preserved beneath ancient overburden. Drilling is continuing with step-out holes to test scale and continuity at Ira Miri, while the company pushes on with its permitting efforts to ramp up exploration at its Werumata and Lautém sites, further south. In parallel with the hunt for manganese, the company is also chasing a large limestone opportunity as part of a partnership and an offtake agreement already in place to monetise the resource. Last month, Estrella struck a binding deal with Indonesian group PT Raka Energi Mandiri (REM) to potentially export up to 500 million tonnes of high-grade limestone from Timor-Leste across the next five years. The agreement gives REM exclusive marketing and off-take rights and includes a performance incentive of up to 500 million share options at 5c each. The joint venture, dubbed Estrella Murak Rai Timor Lda, will retain all revenue from limestone sales. Estrella owns 70 per cent of the joint venture with Timor-Leste's state-owned Murak Rai Timor holding the balance. The material shows up as a clean, coral-rich layer running along the top of the dominant Baucau Formation, which stretches across the company's 195 square kilometre concession. The resource also conveniently sits above its main manganese targets, allowing for dual-resource exploration in a single drill run. Recent assays confirmed the limestone is a premium-grade calcite with minimal impurities, making it highly sought-after for use in cement, glass and agriculture. It is also the perfect neutralising agent in nickel processing and for environmental remediation. With strong backing from the investor, local communities and a budding Timor-Leste mining industry, Estrella appears well-positioned to continue blazing a trail through uncharted territory. The company has already marked itself as a pioneer in the region and now, with $5 million in the bank, it appears ready to dig even deeper. Is your ASX-listed company doing something interesting? Contact:

StockTake: Star Minerals
StockTake: Star Minerals

The Australian

time2 hours ago

  • The Australian

StockTake: Star Minerals

Stockhead's Tylah Tully unpacks the latest from Star Minerals (ASX:SMS), as it endeavours to grow the gold resource at its Tumblegum South gold project. Star is testing for more high-grade lodes that could add to the resource and bolster the potential mine life. Watch the video to learn more. This video was developed in collaboration with Star Minerals, a Stockhead advertiser at the time of publishing. This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

LTR Pharma completes ED study milestone
LTR Pharma completes ED study milestone

Daily Telegraph

time2 hours ago

  • Daily Telegraph

LTR Pharma completes ED study milestone

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. LTR Pharma & co-development partner Aptar Pharma complete extractables study on SPONTAN All identified compounds below ICH safety thresholds for nasal spray-mist erectile dysfunction treatment Leachables study initiated to support FDA regulatory submission under real-world storage conditions Special Report: LTR Pharma has completed a key extractables study for its SPONTAN intranasal spray for erectile dysfunction and kicked off a leachables study as part of a regulatory development program. LTR Pharma (ASX:LTP) said the extractables study, conducted under the supervision of co-development partner Aptar Pharma, evaluated the bottle and pump components of SPONTAN's container closure system. The study confirmed that all detected compounds were below ICH safety thresholds – the internationally recognised standards adopted by the US Food and Drug Administration (FDA) and regulatory authorities worldwide for pharmaceutical impurities. LTR Pharma said the identified compounds would be monitored in the ongoing leachables study. FDA requires extractables and leachables (E&L) studies for all pharmaceutical products to ensure packaging materials do not compromise product safety or efficacy. For nasal spray products, these studies must meet specific regulatory thresholds due to direct tissue exposure. Leachables study now underway The leachables study has started under Aptar Pharma's management, evaluating the potential migration of the compounds from packaging into SPONTAN under real-world storage conditions. LTR Pharma said SPONTAN used industry-standard bottle and pump components as used in multiple FDA-approved nasal spray products. The study will run for at least 24 months to support shelf-life requirements. Consistent with FDA practice for nasal sprays, the company can submit its application once sufficient robust data is available, with study completion continuing post-approval as standard. E&L studies form part of LTR Pharma's comprehensive regulatory strategy following its FDA pre-IND meeting, where the FDA confirmed the proposed development pathway. The company said E&L data were required for the chemistry, manufacturing and controls (CMC) section of its planned new drug application (NDA). With extractables results meeting regulatory requirements, the company progresses to the leachables phase for comprehensive regulatory submission data. Watch: LTR's new appointment Progress on SPONTAN and new US-targeted ROXUS LTR Pharma continues to progress SPONTAN through established regulatory pathways while building commercial foundations through its Australian early access programs. It is also progressing its new ED nasal spray called ROXUS, which offers a fast-track pathway to serve patients through the US personalised healthcare sector. As with SPONTAN, ROXUS is based on the common active ingredient vardenafil. It will be delivered via the 503(a)-compounding pharmacy pathway, which exempts drugs from the usual approval, labelling and manufacturing requirements. "The completion of our extractables study and commencement of the leachables phase keep our regulatory program on schedule,' LTR Pharma executive chairman Lee Rodne said. 'Working with Aptar Pharma provides us with their established expertise in nasal spray device development and FDA submissions. 'These studies are necessary steps in our development pathway, and we look forward to progressing through each regulatory milestone." This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as LTR Pharma completes study milestone for SPONTAN ED treatment

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store